Blood Screening Market Globally Grow at a CAGR of 9.7% by Revenue During the Period 2016-2021

Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital)

(EMAILWIRE.COM, June 14, 2019 ) The global blood screening market is expected to reach USD 2.80 billion by 2021 from USD 1.76 billion in 2016, at a CAGR of 9.7%

Read More @ https://www.marketsandmarkets.com/PressReleases/blood-screening.asp

The major players in the blood screening market are Grifols (Spain), Bio-Rad Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Abbott Laboratories (U.S.), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), and Becton, Dickinson and Company (U.S).

Blood screening is a medical process in which donated blood is mainly tested for HIV1, HIV2, HBV, HCV, malaria, syphilis, and various other infectious diseases. Donated blood is screened for these infectious diseases to reduce the risk of transfusion-transmitted infections (TTIs).

The major factors driving the growth of this market are increasing number of blood donations and blood donors and rising awareness regarding the safety of donated blood. In addition, increasing affordability and adoption of nucleic acid test (NAT) for blood screening, rising demand for donated blood, and increasing prevalence of infectious diseases are also driving the growth of this market.

The major factors driving the growth of this market are increasing number of blood donations and blood donors and rising awareness regarding the safety of donated blood. In addition, increasing affordability and adoption of nucleic acid test (NAT) for blood screening, rising demand for donated blood, and increasing prevalence of infectious diseases are also driving the growth of this market.

Know more about key industry players @ https://www.marketsandmarkets.com/ResearchInsight/blood-screening-market.asp

However, capital expenditure and the operating costs of NAT instruments, lack of mandates for NAT in developing countries, and the emergence of alternative technologies are restraining market growth. Furthermore, some of the major opportunities observed in this market include growing economies such as China and India, the emergence of pathogen reduction technology, and demand of multiplex tests.